Overall rank by patents
#16,873
Across all tracked assignees
USPTO PatentsView assignee record - 17 granted patents across 3 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: D21F (PAPER-MAKING MACHINES; METHODS OF PRODUCING PAPER THEREON).
The verdict
IBS holds 17 US patents across 3 technology areas, rank #16,873 of 50,000 tracked assignees.
IBS Of America has been granted 17 US utility patents between 2015 and 2024, placing IBS Of America at rank #16,873 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.0 claims per patent with primary concentration in D21F (PAPER-MAKING MACHINES; METHODS OF PRODUCING PAPER THEREON). As a US Corporation, IBS Of America is one of the more focused assignees in the PatentsView dataset. By volume, IBS sits between Hytrust, Inc. (17 patents, rank #16,869) and IMS Health Incorporated (17 patents, rank #16,877) - the closest US assignees by grant volume. The composite Innovation Score of 38.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 10 in the 2015–2019 window, a -30% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. IBS Of America's 19.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark IBS Of America against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
HyTrust, Inc.
17 patents
Hydrostor Inc.
17 patents
Hygieia, Inc.
17 patents
I-PEX Inc.
17 patents
ILDONG PHARMACEUTICAL CO., LTD.
17 patents
IMAGE MATCH DESIGN INC.
17 patents
IMMUNOMET THERAPEUTICS INC.
17 patents
IMS Health Incorporated
17 patents
IBS of America
17 patents
What this shows IBS holds 17 patents at rank #16,873, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #16,873 in granted patent volume.
Other assignees with the most granted patents in IBS's primary technology class.
IBS's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
39 Top 40% higher than 60% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 17.6% |
| 2016 | 2 | 11.8% |
| 2017 | 3 | 17.6% |
| 2018 | 1 | 5.9% |
| 2019 | 1 | 5.9% |
| 2021 | 2 | 11.8% |
| 2022 | 1 | 5.9% |
| 2023 | 3 | 17.6% |
| 2024 | 1 | 5.9% |
Top 3 of 3 technology areas
Overall rank by patents
#16,873
Across all tracked assignees
38.6 out of 100
How to use this portfolio
IBS's 17 grants land it in the top 40% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.